This category of entry may appear something of a mixed bag – what unites them is that they all work under constraints – legal or regulatory, and of course that great arbiter, public opinion – that can limit their freedom to operate in quite the way that p
Browsing: Logistics
We arrived with four finalists in what, we must admit, is a bit of a ”mish-mash” of a category, but is essentially the engineering industries and their supply bases. None the less, the assessors believe they have identified a worthy winner.
The Healthcare category produced four shortlisted finalists, although for reasons that are obscure, one fancied entry didn”t continue through the assessment procedure.
Teamwork can mean almost anything – who hasn”t been baffled by a job application asking you to ”demonstrate teamwork”? It”s safe to say though that any organisation making it onto the shortlist of finalists in these Awards must be displaying teamwork
Another major realignment of the European third party logistics market sees the end of one of the UK industry’s most illustrious names. Malory Davies looks at the logic of the deal.
The Outstanding Contribution category of the European Supply Chain Excellence Awards is very different from all the others: you, our readers, nominate the candidates, and you vote by email for the winner (and none of those shenanigans that other less repu
The bestLog project, initiated by the European Commission, is making great progress on its way to establishing its core objective – an exchange platform for the improvement of sustainable supply chain management practice across Europe.
Christian Salvesen was formed in 1872 by the Salvesen family, focusing initially on providing shipping services. For much of its early life the company was one of the world’s largest whaling companies.
Pundits and politicians talk about the need for joined-up thinking, and ERP vendors and systems integrators are equally enthisiastic. But just how joined-up are our supply chains in reality?
Bringing new drugs to market is a very expensive business: typically it can cost over €500 million and – given time limitations on patents – the pharmaceuticals company then has just 5-10 years or so to recoup its investment and make a profit for most the
